Lineage Cell Therapeutics Inc
AMEX: LCTX · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Lineage Cell Therapeutics Inc (LCTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.26M | $-1.24M | $-1.60M | $-4.26M | $-7.73M | $-13.59M | $-19.68M | $-29.51M | $-38.85M | $-44.54M | $-42.33M | $-30.52M | $-30.88M | $-31.95M | $-19.75M | $-23.56M | $1.06M | $-28.57M | $-23.09M | $-18.92M |
| Capital expenditures | $10664.00 | $6473.00 | $859872.00 | $61276.00 | $435771.00 | $961781.00 | $400810.00 | $2.28M | $483097.00 | $5.33M | $2.53M | $1.33M | $3.29M | $440000.00 | $64000.00 | $354000.00 | $413000.00 | $674000.00 | $565000.00 | $522000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $151059.00 | $134518.00 | $488564.00 | $638709.00 | $1.22M | $1.28M | $3.22M | $4.46M | $11.05M | $7.95M | $3.93M | $5.40M | $3.58M | $2.23M | $3.52M | $4.29M | $4.64M | $5.08M | $4.75M |
| Free cash flow | $-1.27M | $-1.25M | $-2.46M | $-4.32M | $-8.17M | $-14.56M | $-20.08M | $-31.79M | $-39.34M | $-49.88M | $-44.85M | $-31.84M | $-34.17M | $-32.39M | $-19.82M | $-23.91M | $646000.00 | $-29.24M | $-23.66M | $-19.44M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | $454000.00 | $34.41M | $40000.00 | $25.15M | $7.24M | — | $37000.00 | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | $1.15M | $23.99M | $12.74M | — | — | $-13.29M | $-14.37M | $23.15M | $23.11M | $-43.47M | — | — | — |
Frequently asked questions
What is Lineage Cell Therapeutics Inc's revenue?
Lineage Cell Therapeutics Inc's trailing twelve-month revenue is $14.78M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is LCTX?
In its most recent fiscal year, LCTX ran a gross margin of 94.19%, an operating margin of -149.62%, and a net margin of -436.47%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does LCTX generate?
LCTX produced $-19.44M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is LCTX's balance sheet healthy?
LCTX holds $40.79M in cash and equivalents against — in long-term debt, on $44.55M of shareholder equity. That debt is best read against the cash flow the business throws off each year.